174 related articles for article (PubMed ID: 15679425)
21. Clinicopathological diagnosis and differential criteria of thrombocythemias in various myeloproliferative disorders by histopathology, histochemistry and immunostaining from bone marrow biopsies.
Thiele J; Kvasnicka HM; Diehl V; Fischer R; Michiels J
Leuk Lymphoma; 1999 Apr; 33(3-4):207-18. PubMed ID: 10221501
[TBL] [Abstract][Full Text] [Related]
22. Stem cell origin of human myeloid blood cell neoplasms.
Fialkow PJ
Verh Dtsch Ges Pathol; 1990; 74():43-7. PubMed ID: 1708632
[TBL] [Abstract][Full Text] [Related]
23. Treatment paradigms in the management of myeloproliferative disorders.
Fruchtman SM
Semin Hematol; 2004 Apr; 41(2 Suppl 3):18-22. PubMed ID: 15190519
[TBL] [Abstract][Full Text] [Related]
24. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos.
Tefferi A; Thiele J; Vardiman JW
Cancer; 2009 Sep; 115(17):3842-7. PubMed ID: 19472396
[TBL] [Abstract][Full Text] [Related]
25. The bone marrow in myeloproliferative and dysmyelopoietic syndromes.
Wolf BC; Neiman RS
Hematol Oncol Clin North Am; 1988 Dec; 2(4):669-94. PubMed ID: 3065324
[TBL] [Abstract][Full Text] [Related]
26. [Utility of bone marrow biopsy in the diagnosis of myeloproliferative neoplasm].
Tovar-Bobadilla JL; Ortiz-Hidalgo C
Gac Med Mex; 2016; 152(3):407-18. PubMed ID: 27335198
[TBL] [Abstract][Full Text] [Related]
27. Systemic mast cell disease (mastocytosis). General aspects and histopathological diagnosis.
Horny HP; Ruck P; Kröber S; Kaiserling E
Histol Histopathol; 1997 Oct; 12(4):1081-9. PubMed ID: 9302569
[TBL] [Abstract][Full Text] [Related]
28. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
Orazi A
Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
[TBL] [Abstract][Full Text] [Related]
29. [Precursors of acute leukemia: myelodysplastic syndromes and myeloproliferative neoplasms].
Kreipe HH
Pathologe; 2011 Nov; 32 Suppl 2():271-6. PubMed ID: 22033685
[TBL] [Abstract][Full Text] [Related]
30. Expression of the c-kit proto-oncogene in myeloproliferative disorders and myelodysplastic syndromes.
Siitonen T; Savolainen ER; Koistinen P
Leukemia; 1994 Apr; 8(4):631-7. PubMed ID: 7512174
[TBL] [Abstract][Full Text] [Related]
31. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group.
Michiels JJ; Juvonen E
Semin Thromb Hemost; 1997; 23(4):339-47. PubMed ID: 9263350
[TBL] [Abstract][Full Text] [Related]
32. A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases.
Vainchenker W; Constantinescu SN
Hematology Am Soc Hematol Educ Program; 2005; ():195-200. PubMed ID: 16304380
[TBL] [Abstract][Full Text] [Related]
33. Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings.
Horny HP; Valent P
Leuk Res; 2001 Jul; 25(7):543-51. PubMed ID: 11377679
[TBL] [Abstract][Full Text] [Related]
34. Cytogenetics of chronic myeloproliferative disorders and related myelodysplastic syndromes.
Adeyinka A; Dewald GW
Hematol Oncol Clin North Am; 2003 Oct; 17(5):1129-49. PubMed ID: 14560778
[TBL] [Abstract][Full Text] [Related]
35. The relationship between the myelodysplastic syndromes and the myeloproliferative disorders.
Bain BJ
Leuk Lymphoma; 1999 Aug; 34(5-6):443-9. PubMed ID: 10492067
[TBL] [Abstract][Full Text] [Related]
36. Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders.
Cortes J; Kantarjian H
Cancer; 2004 May; 100(10):2064-78. PubMed ID: 15139047
[TBL] [Abstract][Full Text] [Related]
37. Bone marrow stromal cells in myeloproliferative disorders.
Hirata J; Takahira H; Kaneko S; Nishimura J; Nawata H
Acta Haematol; 1989; 82(1):35-9. PubMed ID: 2505472
[TBL] [Abstract][Full Text] [Related]
38. WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders.
Michiels JJ; De Raeve H; Hebeda K; Lam KH; Berneman Z; Schroyens W; Schwarz J
Leuk Res; 2007 Aug; 31(8):1031-8. PubMed ID: 17367853
[TBL] [Abstract][Full Text] [Related]
39. Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes.
Haferlach C; Rieder H; Lillington DM; Dastugue N; Hagemeijer A; Harbott J; Stilgenbauer S; Knuutila S; Johansson B; Fonatsch C
Genes Chromosomes Cancer; 2007 May; 46(5):494-9. PubMed ID: 17311250
[TBL] [Abstract][Full Text] [Related]
40. Kit ligand/mast cell growth factor-independent differentiation of mast cells in myelodysplasia and chronic myeloid leukemic blast crisis.
Valent P; Spanblöchl E; Bankl HC; Sperr WR; Marosi C; Pirc-Danoewinata H; Virgolini I; Eichler HG; Agis H; Sillaber C
Blood; 1994 Dec; 84(12):4322-32. PubMed ID: 7527672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
